News

November 20, 2020

On November 5th, five million people watched the premiere of a new CBS show about living donation! “B Positive” is a new comedy sitcom following one man’s living donation journey. Drew, a therapist and single dad, is shocked to find out his kidneys are failing and he’s in urgent need of a transplant. With a rare blood type and lacking friends or family to ask to be his donor, Drew feels hopeless until he runs into an old high school acquaintance—Gina. Gina spontaneously offers to be his donor in her quest to do something bigger than herself.  

Read more ...

October 26, 2020

Dual-organ system enables the measurement of cardiac toxicity arising from breast cancer chemotherapy 

(LOS ANGELES) – Breast cancer is the most commonly occurring cancer for women around the world, and much effort has been spent in the development of therapies to treat this disease. Among these treatments, chemotherapy has been shown to be among the most effective methods; however, the drugs used in these therapies can have adverse side effects, the most serious of which is toxicity to the heart.  In addition to tissue damage to the heart, chemotherapeutic breast cancer drugs can also affect the heart’s pumping ability or result in clinical heart failure. 

Read more ...

October 26, 2020

The Transplant Research and Education Center (TREC) and Health Literacy Media have received the first-place ward in the Special COVID-19 Category at the 2020 ClearMark Awards for “Doing everything you can during COVID-19,” a comprehensive educational guide for kidney and transplant patients. The ClearMark Awards is an annual event hosted by the Center for Plain Language that celebrates achievements in plain language communications by companies, governments, and organizations across North America. Winners are invited to include the ClearMark stamp on their communications materials, signaling the highest standard for clarity and simplicity. 

Read more ...

October 26, 2020 

The Transplant Research and Education Center (TREC) and the Terasaki Institute for Biomedical Innovation, with support from Thermo Fisher Scientific, announce the kickoff of a campaign to capture stories of hope and transformation through the Explore Living Donation Storytelling Project. 

(LOS ANGELES) - The Transplant Research and Education Center (TREC), in partnership with the Terasaki Institute for Biomedical Innovation and One Lambda, Inc., part of Thermo Fisher Scientific and leading producer of in vitro diagnostic products for the HLA transplant community, has launched a six-month mass media campaign for kidney and transplant patients, living donors, and medical providers to raise awareness about the innovative resources available through the Living Donation Storytelling Project. The campaign aims to capture the stories of 500 living donors and inspire, educate and promote living donor kidney transplant (LDKT).  

Read more ...

October 16, 2020

Novel design and strategic use of materials in a pressure-sensitive adhesive strip

(LOS ANGELES) – In recent years, the use of wearable sensing devices has become a part of people’s everyday lives.  Devices such as smart watches, for example, can be used to monitor physical fitness functions such as heart rate, sleep and exercise. 

But advances in technology have opened many more possibilities for monitoring patient health.  Sensors can now measure important health indicators such as metabolites, oxygen or therapeutic drug levels in the blood using wearable or hand-held devices.  This allows patients an easy method of performing continuous, less invasive, real-time testing at home for diagnostic or treatment purposes.  Having such a system profoundly impacts both patient and caregivers’ needs, decreasing the requirement for frequent hospital appointments and encouraging compliance with treatment.

Read more ...

October 7, 2020

Researchers develop a minimally invasive biodegradable microneedle patch as a novel delivery mode for gene therapy applications

(LOS ANGELES) - There is great potential in gene therapy for treating certain types of cancer and genetic defects, immunological diseases, wounds and infections. The therapies work by delivering genes into the patients' cells, which then produce therapeutic proteins to treat the affliction.

When determining the method of delivery for these genes, there are advantages to choosing a local, rather than systemic delivery of the genetic material. With systemic delivery, there is the possibility of unwanted tissue accumulation or of the genetic material becoming unstable. It is also advantageous to target the skin as a site for local delivery, as it is easily accessible and contains fluid and lymph vessels, as well as immune cells upon which the genetic material can act to initiate treatment.

Read more ...

Septemer 23, 2020

(LOS ANGELES) - The Terasaki Institute for Biomedical Innovation welcomes its Director and CEO, Ali Khademhosseini, PhD, who joins the institute with extensive research and leadership experience in the field of biomedical technology.  He is formerly a Professor of Bioengineering at the University of California Los Angeles (UCLA) and a Professor at Harvard Medical School/MIT. He is joining the institute from Amazon, Inc, where he recently completed his sabbatical.  He is recognized as a world-renowned leader in combining micro- and nano-engineering approaches with advanced biomaterials for regenerative medicine applications and has authored over 600 peer-reviewed journal papers.  In addition, Dr. Khademhosseini is a co-founder and Scientific Board Member of Obsidio, Incorporated, a biomaterials technology startup company. 

Read more ...